Antioxidant therapy for chronic hepatitis C after failure of interferon: Results of phase II randomized, double-blind placebo controlled clinical trial

doi:10.3748/wjg.v13.i40.5317

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 40

This Article

(0)

(3786)

(38)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Viral Hepatitis

World J Gastroenterol. Oct 28, 2007; 13(40): 5317-5323
Published online Oct 28, 2007. doi: 10.3748/wjg.v13.i40.5317

Full Size Figure Download Figure

Figure 3 Effect of antioxidant treatment on ALT (A) and AST (B) serum levels in part II with treatment group in solid lines and placebo in dashed lines.

Citation: Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Zabrecky G, Cohen R, Ilan Y. Antioxidant therapy for chronic hepatitis C after failure of interferon: Results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol 2007; 13(40): 5317-5323
URL: https://www.wjgnet.com/1007-9327/full/v13/i40/5317.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i40.5317

Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Zabrecky G, Cohen R, Ilan Y. Antioxidant therapy for chronic hepatitis C after failure of interferon: Results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol 2007; 13(40): 5317-5323 [PMID: 17879400 DOI: 10.3748/wjg.v13.i40.5317]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.